Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From Botswana

Autor: Fallon E. Chipidza, Mukendi K. A. Kayembe, Isaac Nkele, Jason A. Efstathiou, Bruce A. Chabner, Jeremy Abramson, Scott L. Dryden-Peterson, Aliyah R. Sohani

Publikováno v: JCO Global Oncology, Vol , Iss 7, Pp 1620-1632 (2021)

PURPOSEWith intense HIV epidemics, southern African countries have a high burden of classic Hodgkin lymphoma (CHL) and non-Hodgkin lymphoma (NHL). However, suboptimal access to pathology resources limits subtype classification. We sought to assess th

Externí odkaz: https://doaj.org/article/ddace1a607294f3d983e54c1249b4a3a

Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study

Autor: Zola Musimar, Mtonga Mpetani, Jeremy S Abramson, Bruce A Chabner, Zainab Mohamed

Publikováno v: The Oncologist.

Background Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma worldwide and particularly in Africa, where the incidence of HIV is the highest in the world. R-CHOP is the standard of care regimen for DLBCL, bu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6f2c2b01a45f1c32f14e2ab8925a886
https://doi.org/10.1093/oncolo/oyad069

Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC)

Autor: Marko Velimirovic, Lorenzo Gerratana, Andrew A Davis, Whitney L Hensing, Katherine Clifton, Ami N Shah, Paolo D'Amico, Charles S Dai, Elyssa N Denault, Cynthia X Ma, Seth A Wander, Dejan Juric, Massimo Cristofanilli, Bruce A Chabner, Aditya Bardia

Publikováno v: Cancer Research. 82:P2-07

Background: Endocrine therapy with CDK 4/6 inhibitors (ET/CDK4/6i) represents the 1st line therapy for ER+/HER2- ABC. While majority of patients derive clinical benefit with combination therapy, a subset have refractory disease with progression withi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45451e41ea04d68929b99e6bd015bba5
https://doi.org/10.1158/1538-7445.sabcs21-p2-07-02

Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization

Autor: Andrew G Shuman, Matti S Aapro, Benjamin Anderson, Katherine Arbour, Pedro C Barata, Aditya Bardia, Eduardo Bruera, Bruce A Chabner, Herbert Chen, Edwin Choy, Pierfranco Conte, Giuseppe Curigliano, Don Dizon, Eileen O’Reilly, Antonio Tito Fojo, Hans Gelderblom, Timothy A Graubert, Jayne S Gurtler, Evan Hall, Fred R Hirsch, Ahmed Idbaih, David H Ilson, Michael Kelley, Carlo La Vecchia, Heinz Ludwig, Beverly Moy, Hyman Muss, Frans Opdam, Rebecca D Pentz, Marshall R Posner, Jeffrey S Ross, Adrian Sacher, Suresh Senan, Enrique Soto-Perez-de-Celis, Kenneth K Tanabe, Jan B Vermorken, Eric Wehrenberg-Klee, Susan E Bates

Publikováno v: The Oncologist. AlphaMed Press
The oncologist
Shuman, A G, Aapro, M S, Anderson, B, Arbour, K, Barata, P C, Bardia, A, Bruera, E, Chabner, B A, Chen, H, Choy, E, Conte, P, Curigliano, G, Dizon, D, O'Reilly, E, Tito Fojo, A, Gelderblom, H, Graubert, T A, Gurtler, J S, Hall, E, Hirsch, F R, Idbaih, A, Ilson, D H, Kelley, M, La Vecchia, C, Ludwig, H, Moy, B, Muss, H, Opdam, F, Pentz, R D, Posner, M R, Ross, J S, Sacher, A, Senan, S, Perez de Celis, E S, Tanabe, K K, Vermorken, J B, Wehrenberg-Klee, E & Bates, S E 2022, ' Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization ', The Oncologist . https://doi.org/10.1093/oncolo/oyac165

In the context of cancer, whether or not to choose pregnancy termination represents a difficult and multifaceted decision. In this editorial, members of The Oncologist editorial team attempt to contextualize the potential implications of the recent S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2ecc854d9ed429acd22943cfd187fb8
https://hdl.handle.net/1887/3563468

Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer

Autor: Seth A. Wander, Steven J. Isakoff, Megan Yuen, Aparna Raj Parikh, Anthony J. Iafrate, Dejan Juric, Laura Spring, Aditya Bardia, Ryan B. Corcoran, Giuliana Malvarosa, Marko Velimirovic, Leif W. Ellisen, Bruce A. Chabner, Andrzej Niemierko, Neelima Vidula, Arielle Medford, Beverly Moy

Publikováno v: JCO precision oncology. 4

PURPOSE Accurate monitoring of therapeutic response remains an important unmet need for patients with metastatic breast cancer (MBC). Analysis of tumor genomics obtained via circulating tumor DNA (ctDNA) can provide a comprehensive overview of tumor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3db4bd9a0afd939c4d3818935f9e5024
https://pubmed.ncbi.nlm.nih.gov/35050782